On April 10th, Codman Neuro, a neurological division of Johnson & Johnson (J&J), announced that it has acquired Neuravi, a blood-threatening medical technology company based in Galway. The price details of the specific acquisition have not been publicly disclosed, but according to the Irish Times. This number is expected to reach hundreds of millions of euros. This allows Johnson & Johnson to grow rapidly in the stroke treatment market. Neuravi was founded in 2009 by CEO Eamon Brady, Chief Technology Officer David Vale, Chairman John O'Shaughnessy and American radiologist Mahmood Razavi. They have extensively invested in scientific research on different thrombotic variants that cause acute ischemic stroke, invented the blood transport reconstruction device EmboTrap and the second generation product EmboTrapII, and raised more than 25 million euros. Previously, Neurovi received a total of 15 million euros from IPF Partners in 2016 to help develop the second generation of EmbboTrap, a cerebral thrombectomy device. From left: John O'Shaughnessy (Chairman) from Neurova and Eamon Brady (CEO), Justin Lynch, partner at Fountain Healthcare. Image: Andrew Downes What can EmboTrap do? Neuravi's EmboTrap and EmboTrap II revascularization devices are effective in treating common acute ischemic strokes caused by cerebral vascular occlusion. The device treats patients by rapidly capturing blood clots and removing the blood clots in the blood vessels of the brain while not being disturbed by any other blood clots to achieve immediate return to normal blood flow. The Neuravi EmboTrap revascularization device is the first thrombectomy system engineered on the basis of clot studies. It has a new understanding of the mechanics of thrombectomy devices to address a wide range of different types of thrombosis and vascular occlusion. . EmboTrap Seeds,Palay Seeds,Hybrid Palay Seeds,Palay Seeds Variety XIKE AGRICULTURAL GROUP CO . .LTD. , https://www.laoseed.com
